Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VentriPoint DiagnosticsVPTDF -3.66%11 Equity-to-Asset is -8.73 as of Dec. 2025. GuruFocus rates VPTDF with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 852 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks worse than 98.94% on this metric.
The historical rank and industry rank for VentriPoint Diagnostics's Equity-to-Asset or its related term are showing as below:
VPTDF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -8.72 Med: -2.51 Max: 0.87
Current: -8.72
During the past 13 years, the highest Equity to Asset Ratio of VentriPoint Diagnostics was 0.87. The lowest was -8.72. And the median was -2.51.
VPTDF's Equity-to-Asset is ranked worse than 98.94% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs VPTDF: -8.72
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
VentriPoint Diagnostics Equity-to-Asset Related Terms
VentriPoint Diagnostics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VPTDF vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, VentriPoint Diagnostics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
VentriPoint Diagnostics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics (VPTDF) has a Equity-to-Asset of -8.73 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on VentriPoint Diagnostics and its competitors. According to the industry distribution chart, VentriPoint Diagnostics ranks #843 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 98.9%.
Is VentriPoint Diagnostics' Equity-to-Asset too high?
VentriPoint Diagnostics' current Equity-to-Asset is -8.73. Based on the distribution chart, VentriPoint Diagnostics ranks #843 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, VentriPoint Diagnostics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #843 out of 852 companies for Equity-to-Asset. This places VentriPoint Diagnostics in the lower half of its industry. The industry median Equity-to-Asset is 0.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current Equity-to-Asset is -8.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Equity-to-Asset of -8.73. The current Equity-to-Asset is -8.73. VentriPoint Diagnostics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Equity-to-Asset is -8.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
11GF Score
Get the complete analysis for VPTDF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
